Published in Br J Clin Pharmacol on February 01, 1976
Educating doctors to use drugs well. Br J Clin Pharmacol (1976) 4.33
Assessing reports of therapeutic trials. Br Med J (1970) 3.44
Minimum information needed by prescribers. Br Med J (1978) 3.34
Package inserts for prescribed medicines: what minimum information do patients need? Br Med J (1978) 3.21
Quality of Cochrane reviews: assessment of sample from 1998. BMJ (2001) 3.12
Basic information that prescribers are not getting about drugs. Lancet (1987) 2.31
Drug information: is there a need for international uniformity? Drugs (1974) 2.20
Harnessing placebo effects in health care. Lancet (1994) 2.16
Controlling the NHS drugs budget. BMJ (1994) 2.03
Continuing education in therapeutics: aids to discussions on prescribing. Br Med J (1976) 1.91
Camelford water poisoning accident: serial neuropsychological assessments and further observations on bone aluminium. Hum Exp Toxicol (1993) 1.83
Is 'watchful waiting' a real choice for men with prostate cancer? A qualitative study. BJU Int (2002) 1.57
Isothiazolinone preservative: cause of a continuing epidemic of cosmetic dermatitis. Lancet (1989) 1.52
How did such a bad report get published in the EJCP? Trial of paracetamol, ibuprofen and nimesulide in children with upper respiratory infections (B. Ulukol et al., EJCP November 1999, 55: 615-618) Eur J Clin Pharmacol (2000) 1.39
Recognising patients' rights: patchy progress. Lancet (1994) 1.39
The European Medicines Evaluation Agency: open to criticism. Transparency must be coupled with greater rigour. BMJ (1998) 1.38
Unwanted effects of pentagastrin. Clin Pharmacol Ther (1971) 1.38
Medicines Act passes crucial test. Lancet (1988) 1.38
Albumin and the Medicines Control Agency. Lancet (1999) 1.37
Formulary for self-care. Br J Gen Pract (1994) 1.35
Advertisements for medicines in leading medical journals in 18 countries: a 12-month survey of information content and standards. Int J Health Serv (1993) 1.35
The European Medicines Evaluation Agency. BMJ (1996) 1.20
Is there a case for an international medical scientific press council? JAMA (1994) 1.18
Commercial partnerships in chronic disease management: proceeding with caution. BMJ (2000) 1.17
Doctors' anxieties in prescribing. J R Coll Gen Pract (1977) 1.17
Should drug information be an integral part of health care? J R Coll Physicians Lond (1996) 1.07
Many NSAID users who bleed don't know when to stop. BMJ (1998) 1.03
The roles and responsibilities of clinical pharmacology. Br J Clin Pharmacol (1991) 1.03
Misuse of the standard error of the mean. Br J Clin Pharmacol (1988) 0.96
Misoprostol and illegal abortion in Fortaleza, Brazil. Lancet (1993) 0.95
Analysis of patients' narratives posted on social media websites on benfluorex's (Mediator® ) withdrawal in France. J Clin Pharm Ther (2013) 0.94
The long term treatment with beta-carotene in erythropoietic protoporphyria: a controlled trial. Br J Dermatol (1977) 0.94
Medicine and the Law. Driving under the influence of oxazepam: guilt without responsibility? Lancet (1982) 0.93
The short life of a terminal care support team: experience at Charing Cross Hospital. Br Med J (Clin Res Ed) (1985) 0.92
Drugs and the fetal eye. Lancet (1971) 0.92
Blood dyscrasias attributed to chloramphenicol. A review of 576 published and unpublished cases. Acta Med Scand (1972) 0.92
The power of placebo. BMJ (1997) 0.89
Hospital pharmacy committees in England: Their structure, function, and development. Br Med J (1975) 0.88
Information and education as determinants of antibiotic use: report of Task Force 5. Rev Infect Dis (1987) 0.88
Circulatory effects of nicotine aerosol inhalations and cigarette smoking in man. Lancet (1967) 0.87
Managing hypertension in the elderly. Lancet (1992) 0.87
Clioquinol: availability and instructions for use. J Antimicrob Chemother (1976) 0.86
Oral hyoscine butylbromide for irritable bowel syndrome? Br Med J (1979) 0.86
What people close to death say about euthanasia and assisted suicide: a qualitative study. J Med Ethics (2006) 0.86
Effects of hyoscine butylbromide on gut motility. Clin Pharmacol Ther (1969) 0.86
Treatment of whooping cough: the facts. Arch Dis Child (1984) 0.84
Halogenated hydroxyquinolines: still no end. Lancet (1984) 0.83
Continued prescribing of inappropriate drugs in general practice. J Clin Pharm Ther (1995) 0.83
Oestrogens and progestogens for preventing and treating postnatal depression. Cochrane Database Syst Rev (2000) 0.83
Some effects of injected hyoscine butylbromide: a versatile class experiment in human pharmacology. Br J Clin Pharmacol (1977) 0.83
The debate on HIV in Africa. Lancet (2000) 0.81
The effect of a high water intake on the kidney's ability to concentrate the urine in man. 1957. J Am Soc Nephrol (2000) 0.80
Identifying the medical consultants of pharmaceutical companies. Lancet (1979) 0.80
Drug information for patients: bringing together the messages from prescriber, pharmacist and manufacturer. J R Coll Gen Pract (1982) 0.79
Early warnings about drugs-from the stock market. Lancet (1996) 0.79
Blood dyscrasias attributed to chloramphenicol: a review of 641 published and unpublished cases. Postgrad Med J (1974) 0.79
Indications and warnings about chloramphenicol. Lancet (1973) 0.78
Minoxidil: hope for the bald? Lancet (1987) 0.78
Helping patients take responsibility for their own health. Ann Intern Med (2001) 0.78
How informed general practitioners manage mild hypertension: a survey of readers of drug bulletins in 7 countries. International Society of Drug Bulletins (ISDB). Eur J Clin Pharmacol (1996) 0.78
Death of child with supraventricular tachycardia. Lancet (1992) 0.77
Roussel convicted of misleading promotion. Lancet (1987) 0.76
Agranulocytosis and pyrazolone analgesics. Lancet (1984) 0.75
Quantifying ease of swallowing: a comparison of a new lozenge formulation for paracetamol and placebo tablets. Br J Clin Pharmacol (1986) 0.75
Obituaries. Put them on an electronic bulletin board. BMJ (1995) 0.75
Information, compliance and side-effects in patients on dothiepin. Br J Clin Pharmacol (1984) 0.75
Beta-adrenoceptor blockers in atrial fibrillation: the importance of partial agonist activity. Br J Clin Pharmacol (1994) 0.75
How much drug in the tablet? Lancet (1991) 0.75
Treatment of postnatal depression. Additional information would enhance value of study. BMJ (1997) 0.75
Publishing the results of sponsored clinical research. BMJ (1993) 0.75
Clioquinol neurotoxicity among multiple sclerosis patients? J R Coll Gen Pract (1983) 0.75
Acute herpes zoster, postherpetic neuralgia, acyclovir and amitriptyline. Br J Gen Pract (1992) 0.75
Gestrinone in cyclical breast pain. Lancet (1992) 0.75
Letter: Measurement of side effects of drugs. Br Med J (1974) 0.75
Single dose of oral dexamethasone for outpatient croup. Authors should have stated how drug was given. BMJ (1996) 0.75
Glyceryl trinitrate ointment for chronic anal fissure. Lancet (1997) 0.75
Toxicity of ethanol-barbiturate mixtures. J Pharm Pharmacol (1969) 0.75
Letter: reviewing the 36,000 licences. Lancet (1975) 0.75
Departments of clinical pharmacology and therapeutics as sources of data. Postgrad Med J (1977) 0.75
Secret out-of-court settlements in drug-injury cases. Lancet (1999) 0.75
Introduction: the quality of the medical evidence: is it good enough? Int J Technol Assess Health Care (1996) 0.75
Letter: Chloramphenicol. Lancet (1974) 0.75
Cephalothin prophylaxis in open-heart surgery, and other uncontrolled studies. J Antimicrob Chemother (1977) 0.75
Toxicological requirements for a menses-inducer. J Steroid Biochem (1975) 0.75
WHO's model list of essential drugs: a beacon through two decades. Lancet (1995) 0.75
A shared formulary is good for us all. Nurs Stand (1996) 0.75
The contribution of consumers and patients to clinical research. Tokai J Exp Clin Med (1997) 0.75
Euthanasia and palliative care: a pseudoconflict? Lancet (1996) 0.75
Letter: Corticosteroids in Guillain-Barré syndrome. Lancet (1974) 0.75
Prophylactic antimicrobial drug therapy at five London teaching hospitals. A report by the Study Group on the Use of Antimicrobial Drugs. Lancet (1977) 0.75
Patient product information. Therapie (1994) 0.75
Some practical results of the London Medical Group conference on iatrogenic disease. J Med Ethics (1977) 0.75
Letter: Body potassium during prolonged thiazide therapy. Lancet (1975) 0.75
[How best to learn drug therapy. Reference for students and physicians]. Internist (Berl) (1977) 0.75
Witnesses on medication. Med Leg J (1994) 0.75
[Dangers from drugs in aerosols in general and toxic activity of propellants in particular]. Ned Tijdschr Geneeskd (1976) 0.75
Letter: On activated charcoal and nortriptyline. Eur J Clin Pharmacol (1973) 0.75
Letter: Long-term co-trimoxazole and folate depletion. J Antimicrob Chemother (1975) 0.75
Towards a broader agenda for training in critical appraisal. J R Coll Physicians Lond (1999) 0.75
Consumers as instigators and users of drug utilization research. WHO Reg Publ Eur Ser (1993) 0.75